Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Urged to Phase In Quality Metrics Over Two-Year Period

This article was originally published in The Gold Sheet

Executive Summary

Industry consensus emerges: FDA should take it slow with quality metrics, starting with a two-year phase-in period.

You may also be interested in...



FDA To Update Quality Metrics Guidance

It's the only addition to the agency's 2016 agenda.

FDA To Update Quality Metrics Guidance

It's the only addition to the agency's 2016 agenda.

US FDA Would Allow Separation Alternatives In Manufacture Of Low-Risk Beta-Lactams

Proposed guidance revision adds nuance to manufacturing facility separation expectations for beta-lactam compounds that pose less risk of anaphylaxis than penicillin and related antibiotics.

Topics

Latest News
UsernamePublicRestriction

Register

PS000897

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel